(Source: Valneva SE) Not for distribution in Australia, Canada, Japan or the United States Completion of Merger between Vivalis and Intercell to form Valneva Creating a European Biotech Leader in Vaccines and Antibodies Lyon (France), May 28th, 2013 - Valneva SE (Valneva) today announces the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become a leader in its field. Valneva ordinary shares (ISIN FR0004056851) start trading today on the regulated market of NYSE Euronext in Paris under the ticker symbol "VLA.PA" and on the Prime Market segment of the Vienna Stock Exchange under the...
↧